FibroGen, Inc.
FGEN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $21 | $782 | $1,335 |
| - Cash | $118 | $23 | $34 | $50 |
| + Debt | $19 | $93 | $73 | $73 |
| Enterprise Value | – | $91 | $822 | $1,358 |
| Revenue | $1 | $1 | $3 | -$123 |
| % Growth | -20.2% | -50.8% | 102.2% | – |
| Gross Profit | $1 | $1 | $2 | -$103 |
| % Margin | 105.4% | 93.7% | 90.8% | 83.2% |
| EBITDA | -$11 | -$12 | -$14 | -$91 |
| % Margin | -1,010.3% | -856.5% | -517.7% | 73.9% |
| Net Income | $201 | -$8 | $5 | $18 |
| % Margin | 18,646.5% | -564% | 169.4% | -14.6% |
| EPS Diluted | 49.61 | -1.88 | 0.05 | 4.5 |
| % Growth | 2,738.8% | -3,860% | -98.9% | – |
| Operating Cash Flow | -$2 | $13 | $3 | -$30 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$2 | $13 | $3 | -$31 |